(Q53747228)

18 May 2018

title

Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. (English)

1 reference

18 May 2018

0 references

1 reference

Schuh S

1

1 reference

18 May 2018

Johnson DW

2

1 reference

18 May 2018

Callahan S

3

1 reference

18 May 2018

Canny G

4

1 reference

18 May 2018

Levison H

5

1 reference

18 May 2018

language of work or name

English

0 references

publication date

1 April 1995

1 reference

18 May 2018

The Journal of Pediatrics

published in

1 reference

18 May 2018

volume

126

1 reference

18 May 2018

page(s)

639-645

1 reference

18 May 2018

issue

4

1 reference

18 May 2018

A controlled trial of methylprednisolone in the emergency treatment of acute asthma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Anticholinergic therapy of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Nebulised ipratropium and salbutamol in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Determination of dose-response reltionship for nebulized ipratropium in asthmatic children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Anisocoria and aerosolized anticholinergics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Acute angle closure glaucoma associated with nebulised ipratropium bromide and salbutamol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

Paradoxical bronchoconstriction in wheezing infants after nebulised preservative free iso-osmolar ipratropium bromide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2895%2970368-3

10.1016/S0022-3476(95)70368-3

7 January 2021

Identifiers

DOI

1 reference

18 May 2018

PubMed ID

7699549

1 reference

18 May 2018